Monopar Therapeutics (NASDAQ:MNPR - Get Free Report) will likely be announcing its earnings results before the market opens on Thursday, March 27th. Analysts expect the company to announce earnings of ($0.37) per share for the quarter.
Monopar Therapeutics Stock Performance
NASDAQ:MNPR traded down $4.74 during mid-day trading on Friday, hitting $40.00. 59,486 shares of the stock were exchanged, compared to its average volume of 361,132. The stock has a market capitalization of $244.08 million, a price-to-earnings ratio of -20.30 and a beta of 1.18. The firm's 50-day simple moving average is $37.16 and its 200 day simple moving average is $22.67. Monopar Therapeutics has a fifty-two week low of $1.72 and a fifty-two week high of $54.30.
Wall Street Analyst Weigh In
Several analysts recently weighed in on MNPR shares. Piper Sandler reissued an "overweight" rating and set a $76.00 price target on shares of Monopar Therapeutics in a report on Wednesday. HC Wainwright lifted their price objective on Monopar Therapeutics from $22.00 to $40.00 and gave the company a "buy" rating in a report on Wednesday, January 22nd.
Check Out Our Latest Research Report on Monopar Therapeutics
About Monopar Therapeutics
(
Get Free Report)
Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.
Recommended Stories
Before you consider Monopar Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Monopar Therapeutics wasn't on the list.
While Monopar Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
